NEW YORK (GenomeWeb News) — Stem cell technology company VistaGen Therapeutics and the Wisconsin Alumni Research Foundation have signed an agreement for patents to technology developed at the University of Wisconsin – Madison that may be used as predictive drug screening assays.
 
South San Francisco-based VistaGen plans to use the technology to speed up development of customized, next-generation stem cell-based predictive toxicology and drug screening assays.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.